Document is current
Any future updates will be listed below
-
Authors
Köchl, Katharina
Schopper, Tobias
Durmaz, Vedat
Parigger, Lena
Singh, Amit
Krassnigg, Andreas
Cespugli, Marco
Wu, Wei
Yang, Xiaoli
Zhang, Yanchong
Wang, Welson Wen-Shang
Selluski, Crystal
Zhao, Tiehan
Zhang, Xin
Bai, Caihong
Lin, Leon
Hu, Yuxiang
Xie, Zhiwei
Zhang, Zaihui
Yan, Jun
Zatloukal, Kurt
Gruber, Karl
Steinkellner, Georg
Gruber, Christian C.
- License Information
-
More Information
Article History
Received: 17 August 2022
Accepted: 5 January 2023
First Online: 14 January 2023
Competing interests
: K.K., T.S., V.D., L.P., A.S., A.K., M.C. report working for Innophore. W.W., X.Y., Y.Z., W.W.-S.W., C.S., T.Z., X.Z., C.B., L.L., Y.H., Z.X., Z.Z. and J.Y. report working for SignalChem Lifesciences Corporation. K.G., G.S., C.C.G. report being shareholders of Innophore, an enzyme and drug discovery company. C.B., Y.H., Z.X., Z.Z. and J.Y. report being shareholders of SignalChem Lifesciences Corporation. Additionally, G.S. and C.C.G. report being managing directors of Innophore. K.Z. reports being shareholder of Zatloukal Innovations GmbH, a company dedicated to the development of plant based biopharmaceuticals. The research described here is scientifically and financially independent of the efforts in any of the above mentioned companies and open-science.
